GSK to commit $30B to US drug manufacturing

Advertisement

GSK plans to invest $30 billion on research, development and supply chain infrastructure in the U.S. over the next five years. 

The plan includes $1.2 billion for new manufacturing facilities and digital technologies, including a new biologics plant in Upper Merion, Pa., according to a Sept. 17 news release from the devicemaker. 

Other investments will expand into drug substance manufacturing, device and auto injector production and AI capabilities at sites in Pennsylvania, Maryland, North Carolina and Montana. 

The company also said the U.S. will be its largest base for clinical trials over the next five years, according to the release. 

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement